vs
Apellis Pharmaceuticals, Inc.（APLS）与PREFORMED LINE PRODUCTS CO（PLPC）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是PREFORMED LINE PRODUCTS CO的1.2倍（$199.9M vs $173.1M），PREFORMED LINE PRODUCTS CO净利率更高（4.9% vs -29.5%，领先34.4%），PREFORMED LINE PRODUCTS CO同比增速更快（3.6% vs -5.9%），PREFORMED LINE PRODUCTS CO自由现金流更多（$11.8M vs $-14.3M），过去两年PREFORMED LINE PRODUCTS CO的营收复合增速更高（10.8% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
预成型线路产品公司（PLPC）研发、生产和销售适用于输配电、通信及可再生能源基建领域的工程硬件组件，服务全球多地的公用事业、网络运营商及工业客户，提供可提升网络可靠性与运营效率的解决方案。
APLS vs PLPC — 直观对比
营收规模更大
APLS
是对方的1.2倍
$173.1M
营收增速更快
PLPC
高出9.5%
-5.9%
净利率更高
PLPC
高出34.4%
-29.5%
自由现金流更多
PLPC
多$26.1M
$-14.3M
两年增速更快
PLPC
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $173.1M |
| 净利润 | $-59.0M | $8.4M |
| 毛利率 | — | 29.8% |
| 营业利润率 | -25.6% | 6.8% |
| 净利率 | -29.5% | 4.9% |
| 营收同比 | -5.9% | 3.6% |
| 净利润同比 | -62.2% | -19.3% |
| 每股收益（稀释后） | $-0.40 | $1.72 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSPLPC
| Q4 25 | $199.9M | $173.1M | ||
| Q3 25 | $458.6M | $178.1M | ||
| Q2 25 | $178.5M | $169.6M | ||
| Q1 25 | $166.8M | $148.5M | ||
| Q4 24 | $212.5M | $167.1M | ||
| Q3 24 | $196.8M | $147.0M | ||
| Q2 24 | $199.7M | $138.7M | ||
| Q1 24 | $172.3M | $140.9M |
净利润APLSPLPC
| Q4 25 | $-59.0M | $8.4M | ||
| Q3 25 | $215.7M | $2.6M | ||
| Q2 25 | $-42.2M | $12.7M | ||
| Q1 25 | $-92.2M | $11.5M | ||
| Q4 24 | $-36.4M | $10.5M | ||
| Q3 24 | $-57.4M | $7.7M | ||
| Q2 24 | $-37.7M | $9.4M | ||
| Q1 24 | $-66.4M | $9.6M |
毛利率APLSPLPC
| Q4 25 | — | 29.8% | ||
| Q3 25 | — | 29.7% | ||
| Q2 25 | — | 32.7% | ||
| Q1 25 | — | 32.8% | ||
| Q4 24 | — | 33.3% | ||
| Q3 24 | — | 31.1% | ||
| Q2 24 | — | 31.9% | ||
| Q1 24 | — | 31.3% |
营业利润率APLSPLPC
| Q4 25 | -25.6% | 6.8% | ||
| Q3 25 | 48.7% | 7.4% | ||
| Q2 25 | -18.6% | 10.1% | ||
| Q1 25 | -50.0% | 8.8% | ||
| Q4 24 | -12.3% | 10.5% | ||
| Q3 24 | -24.0% | 7.1% | ||
| Q2 24 | -14.7% | 8.1% | ||
| Q1 24 | -36.0% | 8.2% |
净利率APLSPLPC
| Q4 25 | -29.5% | 4.9% | ||
| Q3 25 | 47.0% | 1.5% | ||
| Q2 25 | -23.6% | 7.5% | ||
| Q1 25 | -55.3% | 7.8% | ||
| Q4 24 | -17.1% | 6.3% | ||
| Q3 24 | -29.2% | 5.2% | ||
| Q2 24 | -18.9% | 6.8% | ||
| Q1 24 | -38.5% | 6.8% |
每股收益（稀释后）APLSPLPC
| Q4 25 | $-0.40 | $1.72 | ||
| Q3 25 | $1.67 | $0.53 | ||
| Q2 25 | $-0.33 | $2.56 | ||
| Q1 25 | $-0.74 | $2.33 | ||
| Q4 24 | $-0.30 | $2.13 | ||
| Q3 24 | $-0.46 | $1.54 | ||
| Q2 24 | $-0.30 | $1.89 | ||
| Q1 24 | $-0.54 | $1.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $38.3M |
| 股东权益账面价值 | $370.1M | $475.5M |
| 总资产 | $1.1B | $653.6M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资APLSPLPC
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — | ||
| Q1 24 | $325.9M | — |
总债务APLSPLPC
| Q4 25 | — | $38.3M | ||
| Q3 25 | — | $36.0M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $29.1M | ||
| Q4 24 | — | $20.8M | ||
| Q3 24 | — | $27.2M | ||
| Q2 24 | — | $31.6M | ||
| Q1 24 | $93.1M | $55.0M |
股东权益APLSPLPC
| Q4 25 | $370.1M | $475.5M | ||
| Q3 25 | $401.2M | $466.3M | ||
| Q2 25 | $156.3M | $460.7M | ||
| Q1 25 | $164.2M | $435.8M | ||
| Q4 24 | $228.5M | $422.3M | ||
| Q3 24 | $237.1M | $429.0M | ||
| Q2 24 | $264.3M | $416.2M | ||
| Q1 24 | $266.7M | $413.4M |
总资产APLSPLPC
| Q4 25 | $1.1B | $653.6M | ||
| Q3 25 | $1.1B | $644.6M | ||
| Q2 25 | $821.4M | $631.5M | ||
| Q1 25 | $807.3M | $592.5M | ||
| Q4 24 | $885.1M | $573.9M | ||
| Q3 24 | $901.9M | $592.0M | ||
| Q2 24 | $904.5M | $572.6M | ||
| Q1 24 | $831.9M | $586.1M |
负债/权益比APLSPLPC
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | 0.07× | ||
| Q4 24 | — | 0.05× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | 0.35× | 0.13× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $21.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $11.8M |
| 自由现金流率自由现金流/营收 | -7.1% | 6.8% |
| 资本支出强度资本支出/营收 | 0.1% | 5.9% |
| 现金转化率经营现金流/净利润 | — | 2.60× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $33.3M |
8季度趋势，按日历期对齐
经营现金流APLSPLPC
| Q4 25 | $-14.2M | $21.9M | ||
| Q3 25 | $108.5M | $18.9M | ||
| Q2 25 | $4.4M | $26.9M | ||
| Q1 25 | $-53.4M | $5.7M | ||
| Q4 24 | $19.4M | $24.1M | ||
| Q3 24 | $34.1M | $9.4M | ||
| Q2 24 | $-8.3M | $28.3M | ||
| Q1 24 | $-133.0M | $5.8M |
自由现金流APLSPLPC
| Q4 25 | $-14.3M | $11.8M | ||
| Q3 25 | $108.3M | $8.3M | ||
| Q2 25 | $4.4M | $18.6M | ||
| Q1 25 | $-53.4M | $-5.3M | ||
| Q4 24 | $19.3M | $20.6M | ||
| Q3 24 | — | $5.8M | ||
| Q2 24 | $-8.4M | $24.6M | ||
| Q1 24 | $-133.3M | $1.8M |
自由现金流率APLSPLPC
| Q4 25 | -7.1% | 6.8% | ||
| Q3 25 | 23.6% | 4.7% | ||
| Q2 25 | 2.5% | 10.9% | ||
| Q1 25 | -32.0% | -3.6% | ||
| Q4 24 | 9.1% | 12.3% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | -4.2% | 17.7% | ||
| Q1 24 | -77.3% | 1.3% |
资本支出强度APLSPLPC
| Q4 25 | 0.1% | 5.9% | ||
| Q3 25 | 0.0% | 6.0% | ||
| Q2 25 | 0.0% | 4.9% | ||
| Q1 25 | 0.0% | 7.4% | ||
| Q4 24 | 0.0% | 2.1% | ||
| Q3 24 | 0.0% | 2.4% | ||
| Q2 24 | 0.0% | 2.7% | ||
| Q1 24 | 0.2% | 2.8% |
现金转化率APLSPLPC
| Q4 25 | — | 2.60× | ||
| Q3 25 | 0.50× | 7.21× | ||
| Q2 25 | — | 2.12× | ||
| Q1 25 | — | 0.49× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 3.02× | ||
| Q1 24 | — | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
PLPC
暂无分部数据
